JP Morgan Chase
KNSA icon

JP Morgan Chase’s Kiniksa Pharmaceuticals KNSA Stock Holding History

JP Morgan Chase’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,000
Closed -$581K – 7591
2025
Q2 		$581K Hold
21,000
– – ﹤0.01% 4696
2025
Q1 		$466K Buy
+21,000
New +$432K ﹤0.01% 4825
2023
Q4 		– Sell
-30,000
Closed -$521K – 7706
2023
Q3 		$521K Hold
30,000
– – ﹤0.01% 4451
2023
Q2 		$422K Buy
+30,000
New +$402K ﹤0.01% 4592
2021
Q4 		– Sell
-30,000
Closed -$342K – 6812
2021
Q3 		$342K Buy
+30,000
New +$391K ﹤0.01% 4937

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

JP Morgan Chase's KNSA Position: Q2 2026 in Review

JP Morgan Chase reduced its Kiniksa Pharmaceuticals (KNSA) stake by 71% in Q2 2026, selling an estimated $3.91M and leaving 31,553 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #4142.

JP Morgan Chase first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $9.45M in Q4 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • JP Morgan Chase held 31,553 shares of Kiniksa Pharmaceuticals worth $2.09M as of Q2 2026.
  • JP Morgan Chase sold 75,464 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.91M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4142 holding.
  • JP Morgan Chase first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Kiniksa Pharmaceuticals position peaked at $9.45M in Q4 2024.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.